Ein seltener Fall von Lambert-Eaton-Myasthenischem-Syndrom assoziiert mit Merkelzell-Karzinom und präexistenter Vitiligo

Zusammenfassung

Das Lambert-Eaton-Myasthenische-Syndrom (LEMS) ist eine sehr seltene neurologische Autoimmunerkrankung, für die eine proximal betonte Muskelschwäche charakteristisch ist. Die Erkrankung ist als paraneoplastisches neurologisches Symptom bekannt, das besonders mit neuroendokrinen Tumoren assoziiert ist und v. a. beim kleinzelligen Lungenkarzinom auftreten kann. Das Merkelzell-Karzinom (MCC) ist eine seltene Malignität an der Haut, die eine Tendenz für lokale Rezidive und regionale Lymphknotenmetastasen hat. Es tritt v. a. bei älteren Patienten an den sonnenexponierten Hautarealen als schnell wachsendes intrakutanes Knötchen auf. Hier stellen wir einen Fall von MCC vor, das bei einem vergleichsweise jungen 40-jährigen Patienten mit LEMS und Vitiligo diagnostiziert wurde. Nach einer Überprüfung der Literatur zeigt sich das Auftreten von LEMS mit MCC und Vitiligo als eine Rarität.

Abstract

Lambert-Eaton-myasthenic syndrome (LEMS) is a very rare neurological autoimmune disease characterized by a proximal muscle weakness. The disease can often occur as a paraneoplastic neurological syndrome associated with neuroendocrine malignancies, esp. with a small cell lung carcinoma. The Merkel cell carcinoma (MCC) is a rare malignancy on the skin, which has a tendency for local recurrence and regional lymph node metastases. It occurs especially in older patients on the sun-exposed skin areas as a fast-growing intracutaneous nodule. Here, we present a case of MCC diagnosed in a comparably young 40-year-old male patient with LEMS and vitiligo. After a review of the literature, the simultaneous appearance of LEMS with MCC and vitiligo is an interesting rarity.

• Literatur

• 1 Titulaer MJ, Bethan L, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098-1107
• 2 Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956; 187: 612-613
• 3 Takamori M. Lambert Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol 2008; 15: 145-152
• 4 Tsapakidis K, Samaras I, Papacharalampous K. et al. A Rare Case of Merkel Cell Carcinoma Presented with Lambert Eaton Myasthenic Syndrome without Cutaneous Findings. Cancer Therap Oncol Int J 2017; 4 DOI: 10.19080/CTOIJ.2017.04.555631.
• 5 Bombelli F, Lispi L, Calabro F. et al. A Lambert-Eaton myasthenic syndrome associated to Merkel cell carcinoma: report of a case. Neurol Sci 2015; 36: 1491-1492
• 6 Siau RT, Morris A, Karoo RO. Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. Plast Reconstr Aesthet Surg 2014; 67: e162-164 doi:10.1016/j.bjps.2014.03.014
• 7 Eggers SD, Salomao DR, Dinapoli RP. et al. Paraneoplastic and metastatic neurologic complications of Merkel cell carcinoma. Mayo Clin Proc 2001; 76: 327-330
• 8 Simmons DB, Duginski TM, McClean JC. et al. Lambert-Eaton myasthenic syndrome and merkel cell carcinoma. Muscle Nerve 2016; 53: 325-326
• 9 Iyer JG, Parvathaneni K, Bhatia S. et al. Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol 2016; 75: 541-547
• 10 Pavolucci L, Giannini G, Giannoccaro MP. et al. Paraneoplastic cerebellar degeneration and lambert-eaton myasthenia in a patient with merkel cell carcinoma and voltage-gated calcium channel antibodies. Muscle Nerve 2016; Dec 22. DOI: 10.1002/mus.25530.
• 11 Hoffman WH, Helman SW, Sekul E. et al. Lambert-Eaton Myasthenic syndrome in a child with an autuimmune phenotype. Am J Med Genet A 2003; 119A: 77-80
• 12 Albores Saavedra J, Batich K, Chable Montero F. et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010; 37: 20-27
• 13 Clarke CA, Robbins HA, Tatalovich Z. et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 2015; 107 pii: dju382. DOI: 10.1093/jnci/dju382.
• 14 Heath M, Jaimes N, Lemos B. et al. Clinical characteristics of Merkel cell carcinoma at diagnosisin 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58: 375-381
• 15 Laddha NC, Dwivedi M, Mansuri MS. et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 2013; 22: 245-250
• 16 Gill L, Zarbo A, Isedeh P. et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol 2016; 74: 295-302
• 17 Skeie GO, Apostolski S, Evoli A. et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13: 691-699
• 18 Galanis E, Frytak S, Rowland Jr KM . et al. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. Cancer Immunol Immunother 1999; 48: 85-90
• 19 Kempf W, Mertz KD, Hofbauer GF. et al. Skin cancer in organ transplant recipients. l Pathobiology 2013; 80: 302-309
• 20 Kaae J, Hansen AV, Biggar RJ. et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst 2010; 102: 793-801
• 21 Goh G, Walradt T, Markarov V. et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 2016; 7: 3403-3415
• 22 Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci 2012; 11: 62-68
• 23 Friedlaender MM, Rubinger D, Rosenbaum E. et al. Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 2002; 73: 1894-1850
• 24 Gupta Y, Ammini AC. Vitiligo, hypothyroidism and cardiomyopathy. Indian J Endocrinol Metab 2012; 16: 463-465